Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Corporate Update (April 2015)
5 slides from Actinogen Medical's corporate update, April 2015
Slide 1: Investor Update
April 2015 ISSUE 2 Investor Update In this Issue Expert Advisory Board Appointed 2 Xanamem™ trial update 6 Brain Medicine – the new frontier 7 On the Road 7 Message from the CEO Xanamem™’s novel mechanism of action is something that really excites Welcome to the latest edition of the me given my exp
Slide 2: Xanamem Clinical Advisory Board Appointed
April 2015 ISSUE 2 Xanamem™ Clinical Advisory Board Appointed Professor Colin Masters Neurological Institute of Cleveland Clinic Focusing on therapies such as • Professor, University of and Professor of Medicine (Neurology), Xanamem™, which targets early and Targeting cortisol is a Melbourne, Austra
Slide 3: Xanamem – A new approach to treating Alzheimer's
Xanamem™ – Xanamem™ targets the stress hormone cortisol Actinogen Medical has focussed on a new of cortisone, and its active form cortisol, have particularly in the hippocampus and frontal A new approach approach to treating Alzheimer’s disease. been shown in human and animal models to cortex, the a
Slide 4: Xanamem trial update
April 2015 ISSUE 2 Xanamem™ trial update Presentations: Investment and Research Following the recent successful efficacy and safety study in patients with CEO, Dr Bill Ketelbey will be presenting at a number of Investment and recruitment and dosing of the first Alzheimer’s disease and its prodromal
Slide 5: Actinogen Medical – Fast Facts
April 2015 ISSUE 2 Actinogen Medical Actinogen Medical – Fast Facts For further information, please contact: ASX Code: ACW Market capitalisation: Approximately $40m Dr Bill Ketelbey Chief Executive Officer Actinogen Medical Limited Top Shareholders: Ph: 02 8964 7401 Edinburgh Technology Fund Limited